MedTrace Logo

Effect of Different Doses Of Intrathecal Dexmedetomidine In Combination With Bupivacaine On Spinal Anesthesia

NCT07051512 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-07-04

No results posted yet for this study

Summary

This study is designed to assess the efficacy of different doses of dexmedetomidine in combination with intrathecal hyperbaric bupivacaine on spinal anesthesia and its postoperative analgesic characteristics on patients undergoing infra-umbilical procedures.

Primary outcome:

To ascertain a safe intrathecal dexmedetomidine dose for patients undergoing elective lower abdominal and lower limb surgeries

Secondary outcomes:

Assessment of level of sedation. Assessment of hemodynamic parameters (Blood Pressure -Heart Rate). Assessment of level of sensory \& motor block. Assessment of pain.

Conditions

  • Spinal Anesthesia Evaluation
  • Analgesic
  • Intrathecal Anesthesia

Interventions

DRUG

dexmedetomidine 4μg

patients received (0.5% hyperbaric bupivacaine 12.5 mg + dexmedetomidine 4μg)

DRUG

dexmedetomidine 8 μg

patients received (0.5% hyperbaric bupivacaine 12.5 mg + dexmedetomidine 8 μg)

DRUG

dexmedetomidine 10 μg

patients received (0.5% hyperbaric bupivacaine 12.5 mg + dexmedetomidine 10 μg).

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Marwa Elakraa, Resident · Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2024-06-30
Completion
2024-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07051512 on ClinicalTrials.gov